Victus Femtosecond Laser Platform Gets FDA 501(k) Clearance

Bausch + Lomb and Technolas Perfect Vision GmbH (TPV) received 501(k) clearance from the U.S. Food and Drug Administration (FDA) for the Victus Femtosecond Laser Platform, the first femtosecond laser capable of supporting cataract and corneal procedures on a single platform. The versatile system is designed to reportedly provide greater precision compared to manual cataract surgery techniques, potentially enhancing patient experience.Read more.

B+L Introduces New Products at the Vienna Conference

Bausch + Lomb and Technolas Perfect Vision GmbH (TPV) will introduce the Victus Femtosecond Laser Platform at the upcoming XXIX Congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2011). The platform is a first-of-its-kind technology, capable of supporting cataract, refractive and therapeutic procedures in a single platform. The versatile platform is designed to enable greater precision compared to manual cataract surgery techniques, potentially enhancing the patient experience.Read more.


At the same conference, B+L will introduce "its new enVista glistening-free, hydrophobic acrylic intraocular lens," according to a post on Sys-Con. The lens reportedly "represents a significant step forward in IOL technology. Setting the enVista apart from currently available IOLs is the unique combination of aspheric, aberration-free Advanced Optics technology, designed to deliver enhanced contrast sensitivity and better vision quality, with a clinically proven glistening-free material. In addition, the enVista lens design is intended to minimize posterior capsular opacification (PCO), a common long-term problem with IOLs that can cause patient vision to become clouded post-surgery." Read more.

B+L to Buy Technolas Perfect Vision

Bausch + Lomb and Technolas Perfect Vision GmbH (TPV), a leading ophthalmology laser company, have entered into a definitive agreement providing Bausch + Lomb with an option to purchase all outstanding and unowned TPV shares for a total company value of up to EUR 450 million, according to a company press release. TPV was established in 2009 through a joint venture between Bausch + Lomb and 20/10 Perfect Vision AG to develop and sell advanced refractive and cataract technologies. Read more.